A research team at the University of Vienna, led by medicinal chemist Markus Muttenthaler, has developed a new class of oral ...

A research team has developed a new class of oral peptide therapeutic leads for treating chronic abdominal pain. This groundbreaking innovation offers a safe, non-opioid-based solution for conditions ...

Risk factors for IBS may include HIV infection; however, additional large-scale studies are necessary to draw sound conclusions.

Recent research into the role of gluten and wheat in triggering symptoms for people with Irritable Bowel Syndrome (IBS) ...

Researchers examined the relationship between a diet that provokes inflammation and the risk for irritable bowel syndrome.

University of Queensland researchers have developed a new class of oral painkillers to suppress chronic abdominal pain that ...

Recent data suggest that SIBO may contribute to the pathophysiology of Irritable bowel syndrome (IBS). The purpose of this study was to identify potential predictors of SIBO in patients with IBS.

Research shows links between air pollution and conditions like cardiovascular diseases, neurological disorders, and ...

The primary outcome measure was the change in the Irritable Bowel Syndrome–Symptom Severity Scale (IBS-SSS ... the response ...

The randomised, double-blind, placebo-controlled Phase 2 TrIuMPH trial enrolled a total of 122 patients at two sites in the UK. Patients with confirmed severe IBS-C or IBS-D using Rome IV criteria ...